Ever sinc e cancer and its relationship to the immune system were recognized, there has been interest in using the body's immune system to combat malignant disease . Substantial strides have been made recentl y, although they have not been applied as activ ely in otolaryngology as they have in other fields. Nevertheless, otolaryngologists should be familiar with the exciting progress that has been made in cancer immunotherapy.
Immune stimulation has been successful in causing regression ofmetastatic carcinoma in hum ans . It is now possible to produce recombinant interleukin-2 (IL-2).
This cytokine ordinarily is produced by helper T lymphocytes, and it is important in the regulation of immune reactions. IL-2 has caused regression of metastatic renal carcinoma and metastatic melanoma. In addition, genes involved in coding cancer antigens have been identified, along with the immunogenic peptides associated with these antigens. Consequently, it has become possible to create immune recognition ofcancer antigens through immunization and through adoptive transfer ofantitumor lymphocytes into a lymphodepleted host. 
